Promis Neurosciences Inc (PMN) Stock Price, Quote & News

Company Profile

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers for treating Alzheimer'...

Industry: Biotechnology

Sector: Healthcare

Phone: 416 847 6898

Fax: 416 847 6899

Website: www.promisneurosciences.com

Address:

1920 Yonge Street, Suite 200, Toronto, Canada

MoxeysPal Apr. 4 at 5:40 PM

$PMN if that pilot is captured will he be considered a loser? Trump think so

0 · Reply

sangysmith Apr. 2 at 4:26 PM

$PMN

0 · Reply

OfficialStocktwitsUser Apr. 2 at 11:04 AM

$PMN RSI: 25.75, MACD: -1.2147 Vol: 3.56, MA20: 18.19, MA50: 16.53 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

2 · Reply

MoxeysPal Mar. 31 at 11:50 AM

$PMN take your losses and invest in SAPMF SAPMF CCL

1 · Reply

sangysmith Mar. 31 at 7:28 AM

$PMN As per AI this is not an retail driven stock anymore. ProMIS Neurosciences (PMN) Ownership Breakdown (Based on 8.97 million shares) 🟢 Institutional ~48–50% 4.30M – 4.49M Hedge funds, PIPE investors, biotech specialists 🔵 Insiders ~29–31% 2.60M – 2.78M Management, founders, board 🟡 Retail / Public ~20–23% 1.79M – 2.06M Institutions will entry at 12 to 13 range. PMN is tightly held (≈80% locked) Retail controls only ~20% Stock behavior is institution-driven, not retail-driven

0 · Reply

MoxeysPal Mar. 30 at 9:28 PM

$PMN say goodbye 👋 to the warrants.

0 · Reply

Tubular9988 Mar. 30 at 8:51 PM

$PMN went down 15 million in market value on $450,000 share volume, it will go back up as quick.

0 · Reply

MoxeysPal Mar. 30 at 3:06 PM

$PMN lower lows lower highs

0 · Reply

Tubular9988 Mar. 28 at 5:36 PM

$PMN considering the collapse in the market since the end of February, PMN is holding up very well and is flat. these biotechs with upcoming catalyst are counter cyclical, pmn could hit $60 by early 2027 if results are good.

2 · Reply

sangysmith Mar. 27 at 1:48 PM

$PMN $35

0 · Reply

ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights

Mar 18, 2026, 8:00 AM EDT - 18 days ago

ProMIS Neurosciences to Present Data on ALS & Parkinsons Disease Programs at Alzheimer's Disease/Parkinson's Disease 2026 International Conference (AD/PD™)

Feb 4, 2026, 4:05 PM EST - 2 months ago

ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

Jan 30, 2026, 8:00 AM EST - 2 months ago

ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing

Dec 18, 2025, 7:30 AM EST - 3 months ago

ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer's Disease

Dec 10, 2025, 7:30 AM EST - 4 months ago

ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk

Dec 1, 2025, 7:30 AM EST - 4 months ago

ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer's trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310

Dec 1, 2025, 7:00 AM EST - 4 months ago

ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference

Nov 24, 2025, 8:00 AM EST - 4 months ago

ProMIS Neurosciences Announces Reverse Stock Split

Nov 12, 2025, 7:00 AM EST - 5 months ago

ProMIS Neurosciences Announces Third Quarter 2025 Financial Results & Corporate Highlights

Nov 3, 2025, 4:05 PM EST - 5 months ago

ProMIS Neurosciences to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Oct 22, 2025, 7:30 AM EDT - 5 months ago

ProMIS Neurosciences Strengthens Board with Appointment of Slanix Paul Alex, Pharm.D., President and Portfolio Manager, Public Equity of Ally Bridge Group

Sep 3, 2025, 7:00 AM EDT - 7 months ago

ProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation Cohort in Phase 1b Alzheimer's Trial of PMN310

Aug 13, 2025, 7:00 AM EDT - 8 months ago

ProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate Highlights

Jul 29, 2025, 8:00 AM EDT - 8 months ago

ProMIS Neurosciences to Showcase Protein-Misfolding Drug Discovery Platform & PRECISE-AD Trial Design at the 2025 Alzheimer's Association International Conference

Jul 28, 2025, 7:00 AM EDT - 8 months ago

ProMIS Neurosciences Announces Private Placement Financing

Jul 21, 2025, 8:00 AM EDT - 9 months ago

ProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer's Disease

Jun 17, 2025, 7:00 AM EDT - 10 months ago

ProMIS Neurosciences Presents at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

May 12, 2025, 7:30 AM EDT - 11 months ago

ProMIS Neurosciences Announces First Quarter 2025 Financial Results

Mar 31, 2025, 7:00 AM EDT - 1 year ago

ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights

Mar 24, 2025, 7:00 AM EDT - 1 year ago

ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer's Disease/Parkinson's Disease 2025 International Conference

Mar 13, 2025, 7:00 AM EDT - 1 year ago

ProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual Meeting

Mar 11, 2025, 7:30 AM EDT - 1 year ago

ProMIS Neurosciences to Participate in the 37th Annual Roth Conference

Feb 25, 2025, 7:00 AM EST - 1 year ago

ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer's Disease

Jan 29, 2025, 7:30 AM EST - 1 year ago

ProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech Conference

Jan 13, 2025, 10:30 AM EST - 1 year ago

ProMIS Neurosciences Issues Letter to Shareholders

Nov 14, 2024, 9:15 AM EST - 1 year ago

ProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent Highlights

Oct 30, 2024, 8:00 AM EDT - 1 year ago

ProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer's Disease Conference

Sep 12, 2024, 7:00 AM EDT - 1 year ago

ProMIS Neurosciences to Showcase PMN310's Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences

Sep 5, 2024, 7:00 AM EDT - 1 year ago

ProMIS Neurosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 1, 2024, 7:00 AM EDT - 1 year ago

ProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024

Jul 30, 2024, 8:30 AM EDT - 1 year ago

ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer's Association International Conference

Jul 26, 2024, 8:35 AM EDT - 1 year ago

ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial

Jul 26, 2024, 8:30 AM EDT - 1 year ago

ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing

May 14, 2024, 4:01 PM EDT - 2 years ago

ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights

Apr 30, 2024, 7:00 AM EDT - 2 years ago

ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies

Apr 9, 2024, 7:00 AM EDT - 2 years ago

ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS

Apr 4, 2024, 7:00 AM EDT - 2 years ago

ProMIS Neurosciences to Present in Upcoming Investor Conferences in April

Apr 1, 2024, 4:15 PM EDT - 2 years ago

ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights

Mar 11, 2024, 7:00 AM EDT - 2 years ago

ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio

Feb 22, 2024, 7:00 AM EST - 2 years ago

ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference

Jan 22, 2024, 7:00 AM EST - 2 years ago

ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine

Jan 3, 2024, 7:00 AM EST - 2 years ago

ProMIS Neurosciences, Inc. Announces Leadership Transition

Dec 20, 2023, 7:00 AM EST - 2 years ago

ProMIS Neurosciences Announces Publication on Novel Target for ALS

Nov 20, 2023, 7:00 AM EST - 2 years ago

ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer's Disease

Nov 14, 2023, 4:30 PM EST - 2 years ago

ProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent Highlights

Sep 8, 2023, 7:00 AM EDT - 2 years ago

ProMIS Neurosciences Closes $20.4 Million Private Placement Financing

Sep 6, 2023, 12:18 PM EDT - 2 years ago

ProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 21, 2023, 4:12 PM EDT - 2 years ago

ProMIS Neurosciences Announces $20.4 Million Private Placement Financing

Aug 14, 2023, 5:33 PM EDT - 2 years ago

ProMIS Neurosciences Announces Second Quarter 2023 Financial Results and Recent Highlights

MoxeysPal Apr. 4 at 5:40 PM

$PMN if that pilot is captured will he be considered a loser? Trump think so

0 · Reply

sangysmith Apr. 2 at 4:26 PM

$PMN

0 · Reply

OfficialStocktwitsUser Apr. 2 at 11:04 AM

2 · Reply

MoxeysPal Mar. 31 at 11:50 AM

$PMN take your losses and invest in SAPMF SAPMF CCL

1 · Reply

sangysmith Mar. 31 at 7:28 AM

0 · Reply

MoxeysPal Mar. 30 at 9:28 PM

$PMN say goodbye 👋 to the warrants.

0 · Reply

Tubular9988 Mar. 30 at 8:51 PM

$PMN went down 15 million in market value on $450,000 share volume, it will go back up as quick.

0 · Reply

MoxeysPal Mar. 30 at 3:06 PM

$PMN lower lows lower highs

0 · Reply

Tubular9988 Mar. 28 at 5:36 PM

2 · Reply

sangysmith Mar. 27 at 1:48 PM

$PMN $35

0 · Reply

sangysmith Mar. 26 at 8:18 PM

$PMN PMN 310 to subcutaneous just before the 6 months interim is quite confident and believing in the upcoming results.

1 · Reply

MoxeysPal Mar. 26 at 5:44 PM

$PMN remember the warrants we received our exercisable at $14.40, while the Tranche A & B issued to the wealthy donors are exercisable at below $3. We've been screwed blue and tattooed

0 · Reply

sangysmith Mar. 26 at 7:27 AM

$PMN Saw the 50 million ATM and 200 million shelf offering in S3. They are getting ready for phase 2 / 3 for PMN 310 And other pipelines (from preclinical to phase 1). Atleast per chatgpt, gemini and grok. 🙂

1 · Reply

MoxeysPal Mar. 25 at 11:12 PM

$PMN see it 8 soon. Get OUT

1 · Reply

President_Dwayne_Camacho Mar. 25 at 10:04 PM

$PMN What's up with the $200M shelf offering today when they did a private placement not long ago?

3 · Reply

tonkotsu Mar. 25 at 9:41 PM

$PMN No one buy this dip pleaseee. I’m going to load up the truck once this gets below 10, so please let this drop 😅.

1 · Reply

Tubular9988 Mar. 25 at 8:05 PM

$PMN Anavex sentiment overhung the stock today, but anavex was always a complete dud. this is a good buying opportunity for pmn investors.

1 · Reply

Tubular9988 Mar. 25 at 5:04 PM

$PMN results were fine, no change and good progress continues to be made

1 · Reply

RCPrice Mar. 25 at 3:19 PM

$PMN Worth noting that in release today, the "Milestone Event," which is the release of topline data and which triggers the exercisabilty of the warrants, is now no earlier than "early 2027." In addition, they say, "We are on track to complete a six-month interim analysis of blinded safety and biomarker data in mid-2026." They don't say they will publish the interim analysis, and they don't say they won't. It strikes me as a careful use of language.

1 · Reply

Blueknoser Mar. 25 at 12:39 PM

$PMN https://www.promisneurosciences.com/news-media/press-releases/detail/265/promis-neurosciences-announces-full-year-2025-financial

1 · Reply

Blueknoser Mar. 25 at 12:38 PM

$PMN From the latest press release, this is huge: Development of subcutaneous formulation for PMN310 We have accelerated the development of a subcutaneous formulation of PMN310 and established a dedicated development plan, reflecting our conviction in the potential of this approach to improve patient experience and strengthen the asset's competitive profile.

1 · Reply

Blueknoser Mar. 21 at 1:48 AM

$PMN Food for thought when calculating market cap: EpiSelect™ is a proprietary, patented target discovery platform developed by ProMIS Neurosciences. This technology is designed to identify "Disease Specific Epitopes" (DSEs)—unique molecular surfaces on toxic oligomers (misfolded proteins) that drive neurodegenerative diseases such as Alzheimer's, ALS, and Parkinson's. Key Aspects of ProMIS Neurosciences' EpiSelect™ Patent: Purpose: To generate misfolding-specific antibodies and vaccines that target toxic proteins without interfering with normal protein function. Clinical Application: The platform is used to develop therapeutics like PMN310, which specifically targets toxic amyloid-beta oligomers without affecting normal amyloid-beta monomers or fibrils. Targeted Diseases: Alzheimer's disease (AD), multiple system atrophy (MSA), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and Parkinson’s disease. ProMIS Neurosciences, Inc.

0 · Reply

Market Cap	26.93M
Revenue (ttm)	0.00
Net Income (ttm)	-39.72M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	32,500
Avg Vol	210,152
Day's Range	N/A - N/A
Shares Out	2.15M
Stochastic %K	0%
Beta	-0.17
Analysts	Strong Sell
Price Target	$34.38